Amedisys Inc (NASDAQ:AMED) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

A number of other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Tuesday, May 2nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $57.00 price target on shares of Amedisys in a research report on Friday, April 28th. Mizuho raised shares of Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price target on the stock in a research report on Wednesday, May 3rd. Royal Bank Of Canada reaffirmed a “hold” rating and set a $56.00 price target on shares of Amedisys in a research report on Monday, June 5th. Finally, Stephens upped their price target on shares of Amedisys from $50.00 to $54.00 and gave the company an “equal weight” rating in a research report on Thursday, May 4th. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $56.50.

Shares of Amedisys (AMED) opened at 48.23 on Friday. The firm has a market cap of $1.63 billion, a P/E ratio of 41.22 and a beta of 0.89. The company’s 50-day moving average price is $56.55 and its 200 day moving average price is $54.17. Amedisys has a 52 week low of $34.58 and a 52 week high of $65.91.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. Amedisys’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.42 earnings per share. On average, equities analysts anticipate that Amedisys will post $2.21 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Amedisys Inc (AMED) Upgraded at BidaskClub” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/11/amedisys-inc-amed-upgraded-at-bidaskclub.html.

In related news, Director Bruce D. Perkins acquired 2,000 shares of the business’s stock in a transaction dated Thursday, August 3rd. The shares were bought at an average price of $46.60 per share, with a total value of $93,200.00. Following the transaction, the director now directly owns 15,825 shares of the company’s stock, valued at $737,445. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David B. Pearce sold 1,000 shares of the stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the transaction, the insider now directly owns 10,488 shares in the company, valued at approximately $524,400. The disclosure for this sale can be found here. 2.80% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in AMED. Nationwide Fund Advisors boosted its position in Amedisys by 8.8% in the second quarter. Nationwide Fund Advisors now owns 139,222 shares of the health services provider’s stock worth $8,745,000 after buying an additional 11,268 shares during the period. Ameriprise Financial Inc. boosted its position in Amedisys by 16.6% in the second quarter. Ameriprise Financial Inc. now owns 171,492 shares of the health services provider’s stock worth $10,772,000 after buying an additional 24,458 shares during the period. Teachers Advisors LLC boosted its position in Amedisys by 2.7% in the second quarter. Teachers Advisors LLC now owns 79,605 shares of the health services provider’s stock worth $5,000,000 after buying an additional 2,124 shares during the period. Riverhead Capital Management LLC boosted its position in Amedisys by 75.5% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock worth $121,000 after buying an additional 831 shares during the period. Finally, Timpani Capital Management LLC bought a new position in Amedisys during the second quarter worth about $4,924,000. 99.80% of the stock is currently owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.